Netherlands· NL-c1729245519b
Verquvo 5 mg filmomhulde tabletten
A vericiguat product containing vericiguat, registered in Netherlands by Bayer AG. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Vericiguat is registered in 15 of 19 countries.
Countries holding a registration under ATC C01DX22 (vericiguat), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Vericiguat · ATC C01DX22
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vericiguat costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vericiguat · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$12.83
- ES Spain$9.99
- IT Italy$9.50
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- VERICIGUAT
- Manufacturer
- Bayer AG
- Country
- Netherlands (NL)
- ATC code
- C01DX22
- ATC class
- Vericiguat
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1561
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vericiguat in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVERQUVOBayer AG, Leverkusen
- SwitzerlandVerquvo 5.0 mg, FilmtablettenBayer (Schweiz) AG
- SpainVERQUVO 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULABayer Ag
- IcelandVerquvoBayer AG*
- NorwayVerquvoBayer AG
- PolandVerquvoBayer AG
- SwedenVerquvo 5 mg Filmdragerad tablettBayer AG
- BelgiumVerquvo 5 mgBayer
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Verquvo
- Liechtenstein · Verquvo
- Norway · Verquvo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/338376bf-c314-44c0-9f8f-7f7a4a66ec7e GET /v1/drugs/338376bf-c314-44c0-9f8f-7f7a4a66ec7e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/verquvo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Vericiguat",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126853",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMLAURILSULFAAT",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"VERICIGUAT"
],
"leaflet_url": null,
"authorised_at": "2021/07/16",
"procedure_number": "EMEA/H/C/005319",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1561",
"additional_monitoring": "N"
}See everything about vericiguat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.